Showing results (841-850 of 1,193) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|February 8, 2024
Predicting subgroup treatment effects for a new study: Motivations, results and learnings from running a data challenge in a pharmaceutical corporationBjörn Bornkamp, Silvia Zaoli, Michela Azzarito, et al.Pharmaceutical Statistics|February 8, 2024
Assessing the performance of group-based trajectory modeling method to discover different patterns of medication adherenceAwa Diop, Alind Gupta, Sabrina Mueller, et al.Pharmaceutical Statistics|March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidanceJonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.Pharmaceutical Statistics|February 15, 2024
On sample size calculation in drug interaction trialsPaul Meyvisch, Mitra EbrahimpoorPharmaceutical Statistics|February 24, 2024
Shrinkage priors for isotonic probability vectors and binary data modeling, with applications to dose-response modelingPhilip S Boonstra, Daniel R Owen, Jian KangPharmaceutical Statistics|January 28, 2024
The flaw of averages: Bayes factors as posterior means of the likelihood ratioCharles C Liu, Ron Xiaolong Yu, Murray AitkinPharmaceutical Statistics|April 17, 2024
Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!"Marcel Wolbers, Alessandro Noci, Paul Delmar, et al.Pharmaceutical Statistics|April 17, 2024
Comments on 'standard and reference-based conditional mean imputation': Regulators and trial statisticians be aware!Suzie Cro, Tim P Morris, James H Roger, et al.Pharmaceutical Statistics|April 27, 2024
Optimal sample size division in two-stage seamless designsLindsay R Berry, Joe Marion, Scott M Berry, et al.Pharmaceutical Statistics|April 27, 2024
Current developments of the estimand conceptAlexander Fierenz, Antonia ZapfPageof 120